Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.

Heresco-Levy U, Shoham S, Javitt DC.

Mov Disord. 2013 Apr;28(4):419-24. doi: 10.1002/mds.25306. Epub 2013 Feb 20. Review.

PMID:
23427107
2.

The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.

Labrie V, Roder JC.

Neurosci Biobehav Rev. 2010 Mar;34(3):351-72. doi: 10.1016/j.neubiorev.2009.08.002. Epub 2009 Aug 18. Review.

PMID:
19695284
3.

Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat.

Gozzi A, Herdon H, Schwarz A, Bertani S, Crestan V, Turrini G, Bifone A.

Psychopharmacology (Berl). 2008 Dec;201(2):273-84. doi: 10.1007/s00213-008-1271-z. Epub 2008 Aug 15.

PMID:
18704372
4.

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.

Shim SS, Hammonds MD, Kee BS.

Eur Arch Psychiatry Clin Neurosci. 2008 Feb;258(1):16-27. Epub 2007 Sep 27. Review.

PMID:
17901997
5.
6.

Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia.

Labrie V, Lipina T, Roder JC.

Psychopharmacology (Berl). 2008 Oct;200(2):217-30. doi: 10.1007/s00213-008-1196-6. Epub 2008 Jul 3.

PMID:
18597079
7.

Glycine transporter-1: a new potential therapeutic target for schizophrenia.

Hashimoto K.

Curr Pharm Des. 2011;17(2):112-20. Review.

PMID:
21355838
8.

Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings.

Levin R, Dor-Abarbanel AE, Edelman S, Durrant AR, Hashimoto K, Javitt DC, Heresco-Levy U.

J Psychiatr Res. 2015 Feb;61:188-95. doi: 10.1016/j.jpsychires.2014.12.007. Epub 2014 Dec 24.

PMID:
25554623
9.
10.

The chemical biology of clinically tolerated NMDA receptor antagonists.

Chen HS, Lipton SA.

J Neurochem. 2006 Jun;97(6):1611-26. Review.

11.

The NMDA receptor complex: a long and winding road to therapeutics.

Wood PL.

IDrugs. 2005 Mar;8(3):229-35. Review.

PMID:
15772895
12.

Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.

Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG.

Curr Top Med Chem. 2006;6(8):771-85. Review.

PMID:
16719816
13.

Glutamate as a therapeutic target in psychiatric disorders.

Javitt DC.

Mol Psychiatry. 2004 Nov;9(11):984-97, 979. Review.

PMID:
15278097
14.

Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.

Fiorentini C, Rizzetti MC, Busi C, Bontempi S, Collo G, Spano P, Missale C.

Mol Pharmacol. 2006 Mar;69(3):805-12. Epub 2005 Dec 19.

15.

Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.

Errico F, Bonito-Oliva A, Bagetta V, Vitucci D, Romano R, Zianni E, Napolitano F, Marinucci S, Di Luca M, Calabresi P, Fisone G, Carta M, Picconi B, Gardoni F, Usiello A.

Exp Neurol. 2011 Dec;232(2):240-50. doi: 10.1016/j.expneurol.2011.09.013. Epub 2011 Sep 17.

PMID:
21946266
16.

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Kantrowitz JT, Javitt DC.

Brain Res Bull. 2010 Sep 30;83(3-4):108-21. doi: 10.1016/j.brainresbull.2010.04.006. Epub 2010 Apr 24. Review.

17.
18.

Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Singh SP, Singh V.

CNS Drugs. 2011 Oct 1;25(10):859-85. doi: 10.2165/11586650-000000000-00000.

PMID:
21936588
19.

[Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia].

Nishikawa T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Nov;30(5-6):201-6. Review. Japanese.

PMID:
21226316
20.

Sustained saturating level of glycine induces changes in NR2B-containing-NMDA receptor localization in the CA1 region of the hippocampus.

Imamura Y, Ma CL, Pabba M, Bergeron R.

J Neurochem. 2008 Jun 1;105(6):2454-65. doi: 10.1111/j.1471-4159.2008.05324.x.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk